Home > Healthcare > Pharmaceuticals > Disease Specific Drugs > Spinal Muscular Atrophy Treatment Market

Spinal Muscular Atrophy Treatment Market Trends

  • Report ID: GMI11091
  • Published Date: Aug 2024
  • Report Format: PDF

Spinal Muscular Atrophy Treatment Market Trends

The ongoing innovation and advancement in gene therapy and other treatments for spinal muscular atrophy are anticipated to propel market growth during the analysis period. For instance, animal data presented in 2022 at the American Society of Gene and Cell Therapy (ASGCT), the European Society of Gene and Cell Therapy (ESGCT), and the World Muscle Congress showed that the gene therapy outperformed the benchmark therapy across multiple key endpoints in a mouse model of SMA and exhibited significantly less liver toxicity when administered intravenously. Thus, ongoing research into next-generation gene therapies and small molecule drugs is expanding the range of treatment options, attracting more investment and interest in the market, which is expected to contribute to its growth.
 

Authors: Mariam Faizullabhoy, Gauri Wani

Frequently Asked Questions (FAQ) :

Global spinal muscular atrophy treatment industry was valued at USD 7.3 billion in 2023 and is anticipated to register 19.1% CAGR between 2024 and 2032 due to the increase in diagnosis rate of spinal muscular atrophy in infants and children.

The medication segment in the market held 64.2% revenue share in 2023 due to innovative drugs like Spinraza and Evrysdi targeting SMA’s genetic cause for offering flexible formulation flexible administration options.

North America spinal muscular atrophy treatment market held 45.6% revenue share in 2023 due to supportive rare disease policies, advanced healthcare facilities, and ongoing clinical trials.

American Physical Therapy Association, Astellas Pharma, Beijing Jinlan Gene Technology Co., Ltd., Biogen Inc., Boston's Children Hospital, and Children's Hospital of The King's Daughters, among others.

Spinal Muscular Atrophy Treatment Market Scope

Buy Now


Premium Report Details

  • Base Year: 2023
  • Companies covered: 14
  • Tables & Figures: 343
  • Countries covered: 23
  • Pages: 211
 Download Free Sample